Multicenter Phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcomaHideshi Sugiura, Hideo Mugishima, Toru Hiruma et al.|Journal of Orthopaedic Science|2010Cited by 26
Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional studyHiroshi Koike, Naoki Ishiguro, Tomohisa Sakai et al.|Human Pathology|2018Cited by 26